{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:47:03Z","timestamp":1792453623859,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","trasci.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.transci.2015.05.015","type":"journal-article","created":{"date-parts":[[2015,6,13]],"date-time":"2015-06-13T02:48:16Z","timestamp":1434163696000},"page":"92-94","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Serum eye drop preparation in Australia: Current manufacturing practice"],"prefix":"10.1016","volume":"53","author":[{"given":"Denese C.","family":"Marks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Mondy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerard","family":"Segatchian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peta M.","family":"Dennington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transci.2015.05.015_bib0010","article-title":"A comprehensive review on dry eye disease: diagnosis, medical management, recent developments, and future challenges","author":"Phadatare","year":"2015","journal-title":"Adv Pharm"},{"key":"10.1016\/j.transci.2015.05.015_bib0015","first-page":"240","article-title":"Dry eye: an inflammatory ocular disease","volume":"9","author":"Hessen","year":"2014","journal-title":"J Ophthalmic Vis Res"},{"key":"10.1016\/j.transci.2015.05.015_bib0020","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0002-9394(03)00203-4","article-title":"Abnormal protein profiles in tears with dry eye syndrome","volume":"136","author":"Ohashi","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.transci.2015.05.015_bib0025","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/ICO.0b013e31803dcda2","article-title":"Interleukin-6 and tumor necrosis factor-alpha levels in tears of patients with dry eye syndrome","volume":"26","author":"Yoon","year":"2007","journal-title":"Cornea"},{"key":"10.1016\/j.transci.2015.05.015_bib0030","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/art.1780270415","article-title":"Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca","volume":"27","author":"Fox","year":"1984","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.transci.2015.05.015_bib0035","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1111\/j.1537-2995.2008.01665.x","article-title":"Autologous serum eyedrops: literature review and implications for transfusion medicine specialists","volume":"48","author":"Yamada","year":"2008","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2015.05.015_bib0040","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1442-9071.2008.01895.x","article-title":"Serum growth factor analysis in dry eye syndrome","volume":"36","author":"Bradley","year":"2008","journal-title":"Clin Experiment Ophthalmol"},{"key":"10.1016\/j.transci.2015.05.015_bib0045","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/ICO.0b013e318186321e","article-title":"Time- and temperature-dependent stability of serum growth factor peptides in human autologous serum eye drops","volume":"28","author":"Bradley","year":"2009","journal-title":"Cornea"},{"key":"10.1016\/j.transci.2015.05.015_bib0050","article-title":"Stability of growth factors in autologous serum eyedrops after long-term storage","volume":"1\u20137","author":"L\u00f3pez-Garc\u00eda","year":"2015","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.transci.2015.05.015_bib0055","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1136\/bjo.2003.026211","article-title":"Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease","volume":"88","author":"Noble","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.transci.2015.05.015_bib0060","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ajo.2004.08.040","article-title":"The effect of autologous serum eyedrops in the treatment of severe dry eye disease: a prospective randomized case-control study","volume":"139","author":"Kojima","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.transci.2015.05.015_bib0065","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1097\/ICO.0b013e3181a2a7f6","article-title":"Autologous serum 50% eyedrops in the treatment of persistent corneal epithelial defects","volume":"28","author":"Jeng","year":"2008","journal-title":"Cornea"},{"key":"10.1016\/j.transci.2015.05.015_bib0070","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1089\/jop.2012.0002","article-title":"Allogeneic serum eye drops for the treatment of dry eye patients with chronic graft-versus-host disease","volume":"28","author":"Na","year":"2012","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.transci.2015.05.015_bib0075","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3109\/02713683.2013.824987","article-title":"The application of autologous serum eye drops in severe dry eye patients; subjective and objective parameters before and after treatment","volume":"39","author":"Jirsova","year":"2014","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.transci.2015.05.015_bib0080","first-page":"619","article-title":"The efficacy of autologous serum eye drops for severe dry eye syndrome: a randomized double-blind crossover study","volume":"252","author":"Celebi","year":"2014","journal-title":"Cornea"},{"key":"10.1016\/j.transci.2015.05.015_bib0085","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3109\/02713683.2012.720340","article-title":"Comparison of autologous serum eye drops with different diluents","volume":"38","author":"Cho","year":"2013","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.transci.2015.05.015_bib0090","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/aos.12386","article-title":"Ready-made allogeneic ABO-specific serum eye drops: production from regular male blood donors, clinical routine, safety and efficacy","volume":"92","author":"Harritsh\u00f8j","year":"2014","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.transci.2015.05.015_bib0095","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1097\/ICO.0000000000000271","article-title":"Long term use of autologous serum 50% eye drops for the treatment of dry eye disease","volume":"33","author":"Hussain","year":"2014","journal-title":"Cornea"},{"key":"10.1016\/j.transci.2015.05.015_bib0100","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/sj.eye.6703079","article-title":"Allogeneic serum eye drops for the treatment of persistent corneal epithelial defect","volume":"23","author":"Chiang","year":"2009","journal-title":"Eye"},{"issue":"8","key":"10.1016\/j.transci.2015.05.015_bib0105","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD009327.pub2","article-title":"Autologous serum eye drops for dry eye (Review)","author":"Pan","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.transci.2015.05.015_bib0110","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/02713680601147690","article-title":"Albumin rescues ocular epithelial cells from cell death in dry eye","volume":"32","author":"Higuchi","year":"2007","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.transci.2015.05.015_bib0115","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1089\/jop.2014.0161","article-title":"Treatment of severe ocular surface disorders with albumin eye drops","volume":"31","author":"Schargus","year":"2015","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.transci.2015.05.015_bib0120","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/bmt.2012.64","article-title":"Autologous platelet lysate for treatment of refractory ocular GVHD","volume":"47","author":"Pezzotta","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transci.2015.05.015_bib0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2014.12.027","article-title":"Platelet-rich plasma as treatment for persistent ocular epithelial defects","author":"Ronci","year":"2015","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.transci.2015.05.015_bib0130","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.exer.2015.02.016","article-title":"Plasma rich in growth factors (PRGF) eye drops stimulates scarless regeneration compared to autologous serum in the ocular surface stromal fibroblasts","volume":"135","author":"Anitua","year":"2015","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.transci.2015.05.015_bib0135","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.transci.2014.08.006","article-title":"Multifaceted regenerative lives of expired platelets in the second decade of the 21st century","volume":"51","author":"Burnouf","year":"2014","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.transci.2015.05.015_bib0140","author":"Australian Red Cross Blood Service"},{"key":"10.1016\/j.transci.2015.05.015_bib0145","author":"New Zealand Blood Service"},{"key":"10.1016\/j.transci.2015.05.015_bib0150","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/bjophthalmol-2012-301668","article-title":"Allogeneic serum eye drops: time these became the norm?","volume":"96","author":"Badami","year":"2012","journal-title":"Br J Ophthalmol"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050215001081?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050215001081?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T17:50:03Z","timestamp":1537552203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050215001081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S1473050215001081"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2015.05.015","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum eye drop preparation in Australia: Current manufacturing practice","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2015.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown copyright \u00a9 2015 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}